Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Pharmaceutical maker Amgen will lower the sticker price of its cholesterol drug Repatha (generic: evolocumab) by 60% to $5,850 a year, it announced Wednesday. Repatha is a PCSK9 inhibitor shown to ...

Amgen's cholesterol drug Repatha has a new use in Europe, as the company continues in its battle with Sanofi/Regeneron's rival therapy, Praluent. A PCSK9 inhibitor class drug, Repatha (evolocumab) is ...

Amgen has been trying since 2015 to protect its PCSK9 cholesterol drug Repatha by keeping Sanofi and Regeneron’s rival Praluent off the market, even going as far as to ask the U.S. Supreme Court to ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...